Improving efficiency

Copyright © 2026 LexisNexis
This Overview signposts the core materials to help practitioners improve efficiency in life sciences legal, regulatory and compliance work, with links to practice notes, precedents and workflows.

Efficiency is a legal issue because regulated activities must be delivered without compromising compliance under frameworks such as the Human Medicines Regulations 2012, the Medicines and Medical Devices Act 2021, EU Regulations 2017/745 and 2017/746 on medical devices and in vitro diagnostics, GxP requirements, and data protection laws (UK GDPR and the Data Protection Act 2018). Post‑Brexit regulatory divergence between MHRA and EU authorities adds complexity that benefits from streamlined processes.

Key themes include contract lifecycle efficiency for R&D, clinical, manufacturing, distribution and market access arrangements, while managing competition law risk (Competition Act 1998) in collaborations. Practitioners should consider template suites, playbooks, clause libraries, and approval matrices; supplier due diligence and outsourcing controls; inspection‑ready documentation, including validated electronic systems. For clinical and pharmacovigilance functions, focus on GCP/GVP documentation, QPPV oversight, signal management and audit trails. For devices, ensure conformity pathways, vigilance and UDI data are systematised. Public procurement (Public Contracts Regulations 2015) and transparency reporting (ABPI Code) require timely, accurate processes....

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

MHRA regulatory reform amendments tabled in Health Bill

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that the government has tabled amendments to the Health Bill to support...

Life Sciences weekly highlights—3 September 2026

This week's edition of Life Sciences weekly highlights includes news that the MHRA has tabled three amendments to the Health Bill aimed at modernising...

EMA and HMA consult on draft EMRN data standards framework

The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have published a draft data standards framework for consultation. The...

NICE confirms adoption of UK EQ-5D-5L value set for medicine appraisals

The National Institute for Health and Care Excellence (NICE) has confirmed that it will adopt the UK EQ-5D-5L value set for measuring health-related...

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of
Late payment penalties—inheritance tax

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of